PMID- 16966829
OWN - NLM
STAT- MEDLINE
DCOM- 20070423
LR  - 20220309
IS  - 0918-8959 (Print)
IS  - 0918-8959 (Linking)
VI  - 53
IP  - 6
DP  - 2006 Dec
TI  - Possible relationship between adiponectin and renal tubular injury in diabetic 
      nephropathy.
PG  - 745-52
AB  - Adiponectin is an adipose-derived protein which has anti-inflammatory and 
      anti-atherogenic properties in addition to insulin-sensitizing effects. To date, 
      the role of adiponectin in the pathogenesis of diabetic nephropathy remains 
      unclear. The aim of the present study was to explore the relationship between 
      adiponectin and renal tubular injury in diabetic nephropathy. We determined serum 
      and urinary adiponectin levels in type 2 diabetic patients with normoalbuminuria 
      (n = 19), microalbuminuria (n = 18), and overt diabetic nephropathy (n = 16), and 
      then analyzed the correlations between serum and urinary adiponectin, urinary 
      N-acetylglucosaminidase (NAG) as a clinical marker of renal tubular injury, 
      urinary monocyte chemoattractant protein-1 (MCP-1) as an inflammatory marker in 
      renal tubulointerstitium, and clinical markers of renal disease. Notably, serum 
      and urinary adiponectin levels were significantly increased in patients with 
      overt diabetic nephropathy compared to those with normoalbuminuria and 
      microalbuminuria. In univariate linear regression analysis, serum adiponectin 
      levels were positively correlated with serum creatinine (r = 0.648, P<0.0001), 
      urinary albumin (r = 0.583, P<0.0001), urinary NAG (r = 0.406, P<0.01), urinary 
      MCP-1 (r = 0.514, P<0.0001), and urinary adiponectin (r = 0.691, P<0.0001) levels 
      in all diabetic patients. Urinary adiponectin levels were also positively 
      correlated with serum creatinine (r = 0.729, P<0.0001), urinary albumin (r = 
      0.799, P<0.0001), urinary NAG (r = 0.701, P<0.0001), and urinary MCP-1 (r = 
      0.801, P<0.0001) levels in all diabetic patients. Multiple linear regression 
      analysis showed that serum creatinine and urinary adiponectin levels were 
      independently associated with serum adiponectin levels (r(2) = 0.522), and that 
      serum creatinine, urinary NAG, urinary MCP-1, and serum adiponectin levels were 
      independent determinants of urinary adiponectin levels (r(2) = 0.851). These 
      results collectively indicate that renal insufficiency and tubular injury 
      possibly play a contributory role in increases in serum and urinary adiponectin 
      levels in overt diabetic nephropathy. We presume that an increase in circulating 
      adiponectin in overt diabetic nephropathy might be a physiological response to 
      mitigate renal tubular injury and to prevent the further progression of diabetic 
      nephropathy through its anti-inflammatory and anti-atherogenic effects.
FAU - Fujita, Hiroki
AU  - Fujita H
AD  - Division of Endocrinology, Metabolism, and Geriatric Medicine, Department of 
      Internal Medicine, Akita University School of Medicine, Japan.
FAU - Morii, Tsukasa
AU  - Morii T
FAU - Koshimura, Jun
AU  - Koshimura J
FAU - Ishikawa, Motoko
AU  - Ishikawa M
FAU - Kato, Masako
AU  - Kato M
FAU - Miura, Takeshi
AU  - Miura T
FAU - Sasaki, Hiroshi
AU  - Sasaki H
FAU - Narita, Takuma
AU  - Narita T
FAU - Ito, Seiki
AU  - Ito S
FAU - Kakei, Masafumi
AU  - Kakei M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20060912
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Adiponectin)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 3.2.1.52 (Acetylglucosaminidase)
SB  - IM
MH  - Acetylglucosaminidase/urine
MH  - Adiponectin/*blood/*urine
MH  - Aged
MH  - Albuminuria
MH  - Chemokine CCL2/urine
MH  - Creatinine/blood
MH  - Diabetes Mellitus, Type 2/blood/physiopathology/urine
MH  - Diabetic Nephropathies/*blood/physiopathology/*urine
MH  - Female
MH  - Humans
MH  - Kidney Tubules/*physiopathology
MH  - Male
MH  - Middle Aged
EDAT- 2006/09/13 09:00
MHDA- 2007/04/24 09:00
CRDT- 2006/09/13 09:00
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2007/04/24 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
AID - JST.JSTAGE/endocrj/K06-016 [pii]
AID - 10.1507/endocrj.k06-016 [doi]
PST - ppublish
SO  - Endocr J. 2006 Dec;53(6):745-52. doi: 10.1507/endocrj.k06-016. Epub 2006 Sep 12.